Silodosin new selective A1-adrenoblocker

Medications that inhibit adrenergic receptors, are used in clinical practice for a quite long time since 1918. Discovery of different subtypes of a-adrenergic receptors and the clarification of their role allowed to create selective a1-blockers, which, compared with non-selective a-blockers have far less side effects on the cardiovascular system. Silodosin clinical efficacy in treatment of benign prostatic hyperplasia was confirmed in three double-blind randomized studies Two of them were conducted in the U.S., one in Europe. U.S. trial compared silodozin with placebo. European trial compared silodozin with placebo and tamsulosin. The treatment course was 12 weeks. The treatment results were assessed both by subjective (IPSS scale), and objective methods (uroflowmetry). Due to its selectivity that exceeds all available analogues silodozin has safety advantages in the treatment of BPH in patients eith hypertensia, tachycardia, tachyarrhythmia, especially against the background of coronary heart disease, peptic ulcer and duodenal ulcer, hyperacid gastritis. Silodosin does not increase the risk of hypotension in patients taking antihypertensive medications, and in patients taking inhibitors of phosphodiesterase type 5.